<pages>
<page bbox="0.000,0.000,720.000,540.000" id="1" rotate="0">
<textbox bbox="131.710,267.980,606.809,493.649" id="0" size="24.006">Testimony of Sidney M. Wolfe MD 
and Elizabeth Barbehenn, Ph.D.,  
Public Citizen&#8217;s Health Research Group 
FDA Non-Prescription and Endocrine 
and Metabolic Drug Advisory Committees 
Hearing on Possible Switch of  
Orlistat to OTC Status 
January 23, 2006 <textline bbox="175.300,469.625,556.633,493.649" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="24.024">Testimony of Sidney M. Wolfe MD </textline>
<textline bbox="182.140,440.810,556.564,464.810" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="24.000">and Elizabeth Barbehenn, Ph.D.,  </textline>
<textline bbox="141.070,412.010,590.734,436.010" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="24.000">Public Citizen&#8217;s Health Research Group </textline>
<textline bbox="154.510,383.210,577.396,407.210" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="24.000">FDA Non-Prescription and Endocrine </textline>
<textline bbox="131.710,354.405,606.809,378.429" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="24.024">and Metabolic Drug Advisory Committees </textline>
<textline bbox="197.500,325.580,547.780,349.580" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="24.000">Hearing on Possible Switch of  </textline>
<textline bbox="240.820,296.780,491.236,320.780" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="24.000">Orlistat to OTC Status </textline>
<textline bbox="269.980,267.980,461.980,291.980" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="24.000">January 23, 2006 </textline>
</textbox>
<textbox bbox="88.032,115.717,667.123,224.562" id="1" size="32.048">Principles to Consider When Deciding 
on an Rx-to-OTC Switch: 
Application in the Case of Orlistat <textline bbox="88.032,192.522,667.123,224.562" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">Principles to Consider When Deciding </textline>
<textline bbox="193.630,154.122,570.285,186.162" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">on an Rx-to-OTC Switch: </textline>
<textline bbox="120.910,115.717,634.062,147.781" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.064">Application in the Case of Orlistat </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="2" rotate="0">
<textbox bbox="25.200,438.572,583.240,470.612" id="0" size="32.04">1. Ease / possibility of self-diagnosis <textline bbox="25.200,438.572,583.240,470.612" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">1. Ease / possibility of self-diagnosis </textline>
</textbox>
<textbox bbox="51.840,59.192,696.510,390.607" id="1" size="27.967200000000002">The actual use trial demonstrated that a significant  
proportion of people choosing orlistat were not very  
overweight. FDA data from the trial shows that in  
age groups 36-40 and 41-45 years, 16% of women  
had starting BMI&#8217;s of less than 25.3 kg/m2 and  
26.4 kg/m2,  respectively. Almost one-third of  
women had a BMI of less than 30 kg/m2.  Self  
diagnosis, or the lack thereof, of conditions as  
diabetes, hypertension, often associated with  
obesity is also a problem. <textline bbox="51.840,362.623,686.377,390.607" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">The actual use trial demonstrated that a significant  </textline>
<textline bbox="52.200,328.038,696.510,355.998" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">proportion of people choosing orlistat were not very  </textline>
<textline bbox="52.200,294.438,663.182,322.398" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">overweight. FDA data from the trial shows that in  </textline>
<textline bbox="52.200,260.833,691.389,288.817" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">age groups 36-40 and 41-45 years, 16% of women  </textline>
<textline bbox="52.200,227.218,636.201,255.178" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">had starting BMI&#8217;s of less than 25.3 kg/m2 and  </textline>
<textline bbox="52.200,193.618,617.306,221.578" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">26.4 kg/m2,  respectively. Almost one-third of  </textline>
<textline bbox="52.200,160.018,631.979,187.978" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">women had a BMI of less than 30 kg/m2.  Self  </textline>
<textline bbox="52.200,126.413,629.118,154.397" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">diagnosis, or the lack thereof, of conditions as  </textline>
<textline bbox="52.200,92.792,619.872,120.752" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">diabetes, hypertension, often associated with  </textline>
<textline bbox="52.200,59.192,368.595,87.152" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">obesity is also a problem. </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="3" rotate="0">
<textbox bbox="98.952,469.142,621.110,501.182" id="0" size="32.04">Ease / possibility of self-diagnosis <textline bbox="98.952,469.142,621.110,501.182" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">Ease / possibility of self-diagnosis </textline>
</textbox>
<textbox bbox="33.840,26.176,714.473,438.452" id="1" size="32.044000000000004">Current research on cardiovascular risk  
stresses assessment of global risk rather than  
focusing simply on treating just one possible  
risk factor. This explains the current labeling on  
prescription orlistat: &#8220;The long-term effects of  
orlistat on morbidity or mortality associated with  
obesity have not been established&#8221;. The need  
to consider all factors including hypertension,  
diabetes, smoking, family history and others is  
one of the major arguments against OTC  
availability of anti-hypertensive, cholesterol- 
lowering, diabetes and weight reduction drugs. <textline bbox="33.840,406.412,600.371,438.452" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">Current research on cardiovascular risk  </textline>
<textline bbox="34.200,371.847,693.019,403.911" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">stresses assessment of global risk rather than  </textline>
<textline bbox="34.200,337.262,668.400,369.302" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">focusing simply on treating just one possible  </textline>
<textline bbox="34.200,302.702,708.386,334.742" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">risk factor. This explains the current labeling on  </textline>
<textline bbox="34.200,268.142,676.523,300.182" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">prescription orlistat: &#8220;The long-term effects of  </textline>
<textline bbox="34.200,233.562,714.473,265.602" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">orlistat on morbidity or mortality associated with  </textline>
<textline bbox="34.200,199.002,688.930,231.042" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">obesity have not been established&#8221;. The need  </textline>
<textline bbox="34.200,164.442,680.959,196.482" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">to consider all factors including hypertension,  </textline>
<textline bbox="34.200,129.877,696.674,161.941" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">diabetes, smoking, family history and others is  </textline>
<textline bbox="34.200,95.292,622.038,127.332" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">one of the major arguments against OTC  </textline>
<textline bbox="34.200,60.736,652.549,92.776" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">availability of anti-hypertensive, cholesterol- </textline>
<textline bbox="34.200,26.176,693.231,58.216" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">lowering, diabetes and weight reduction drugs. </textline>
</textbox>
<curve bbox="330.720,269.160,667.440,271.560" linewidth="0" pts="330.720,271.560,499.080,271.560,667.440,271.560,667.440,269.160,499.080,269.160,330.720,269.160" />
<curve bbox="34.200,234.600,705.480,237.000" linewidth="0" pts="34.200,237.000,202.020,237.000,369.840,237.000,537.660,237.000,705.480,237.000,705.480,234.600,537.660,234.600,369.840,234.600,202.020,234.600,34.200,234.600" />
<curve bbox="34.200,200.040,517.320,202.440" linewidth="0" pts="34.200,202.440,195.240,202.440,356.280,202.440,517.320,202.440,517.320,200.040,356.280,200.040,195.240,200.040,34.200,200.040" />
</page>
<page bbox="0.000,0.000,720.000,540.000" id="4" rotate="0">
<textbox bbox="8.928,416.342,684.003,525.231" id="0" size="32.048">GSK explaining why blood pressure and serum  
lipids were not included in integrated efficacy  
summary: <textline bbox="8.928,493.167,684.003,525.231" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">GSK explaining why blood pressure and serum  </textline>
<textline bbox="25.128,454.742,667.562,486.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">lipids were not included in integrated efficacy  </textline>
<textline bbox="271.780,416.342,412.243,448.382" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">summary: </textline>
</textbox>
<textbox bbox="33.840,131.317,686.054,278.601" id="1" size="32.052">&#8220;..mainly because the [OTC] indication is to  
promote weight loss and all other benefits  
achieved from orlistat would be most properly  
handled under the supervision of a physician.&#8221; <textline bbox="33.840,246.537,651.938,278.601" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">&#8220;..mainly because the [OTC] indication is to  </textline>
<textline bbox="34.200,208.122,632.739,240.162" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">promote weight loss and all other benefits  </textline>
<textline bbox="34.200,169.722,686.054,201.762" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">achieved from orlistat would be most properly  </textline>
<textline bbox="34.200,131.317,686.029,163.381" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">handled under the supervision of a physician.&#8221; </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="5" rotate="0">
<textbox bbox="119.230,454.742,600.855,486.782" id="0" size="32.04">FDA Response to GSK Statement <textline bbox="119.230,454.742,600.855,486.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">FDA Response to GSK Statement </textline>
</textbox>
<textbox bbox="25.200,372.567,649.745,404.631" id="1" size="32.064">&#8226; &#8220;GSK seems to be saying that overweight  <textline bbox="25.200,372.567,649.745,404.631" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">&#8226; &#8220;GSK seems to be saying that overweight  </textline>
</textbox>
<textbox bbox="52.200,103.692,697.392,366.182" id="2" size="32.04685714285714">individuals with weight-related co-morbidities  
such as type 2 diabetes, hypertension or  
dyslipidemia are inappropriate candidates for  
OTC orlistat because weight loss in such  
patients will require management of a  
physician to ensure that such changes will  
favorably alter overall cardiovascular risks.&#8221; <textline bbox="52.200,334.142,693.544,366.182" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">individuals with weight-related co-morbidities  </textline>
<textline bbox="52.200,295.742,635.296,327.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">such as type 2 diabetes, hypertension or  </textline>
<textline bbox="52.200,257.337,697.392,289.401" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">dyslipidemia are inappropriate candidates for  </textline>
<textline bbox="52.200,218.922,639.077,250.962" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">OTC orlistat because weight loss in such  </textline>
<textline bbox="52.200,180.522,592.430,212.562" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">patients will require management of a  </textline>
<textline bbox="52.200,142.117,658.434,174.181" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">physician to ensure that such changes will  </textline>
<textline bbox="52.200,103.692,665.638,135.732" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">favorably alter overall cardiovascular risks.&#8221; </textline>
</textbox>
<textbox bbox="7.200,10.999,313.103,29.023" id="3" size="18.024">FDA review by J. Golden MD, page 22 <textline bbox="7.200,10.999,313.103,29.023" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="18.024">FDA review by J. Golden MD, page 22 </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="6" rotate="0">
<textbox bbox="202.780,454.742,517.349,486.782" id="0" size="32.04">Further FDA response <textline bbox="202.780,454.742,517.349,486.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">Further FDA response </textline>
</textbox>
<textbox bbox="25.200,354.542,570.831,386.582" id="1" size="32.04">&#8226; It is difficult to imagine the proposed  <textline bbox="25.200,354.542,570.831,386.582" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">&#8226; It is difficult to imagine the proposed  </textline>
</textbox>
<textbox bbox="52.200,200.922,679.639,348.182" id="2" size="32.046">dichotomization of the target population into  
mildly-to-moderate overweight adults with  
and without weight-related co-morbidities  
...succeeding in the real world  <textline bbox="52.200,316.142,679.639,348.182" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">dichotomization of the target population into  </textline>
<textline bbox="52.200,277.742,649.340,309.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">mildly-to-moderate overweight adults with  </textline>
<textline bbox="52.200,239.337,642.002,271.401" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">and without weight-related co-morbidities  </textline>
<textline bbox="52.200,200.922,484.131,232.962" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">...succeeding in the real world  </textline>
</textbox>
<textbox bbox="7.200,5.748,313.128,23.748" id="3" size="18.0">FDA review by J. Golden MD, page 22 <textline bbox="7.200,5.748,313.128,23.748" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="18.000">FDA review by J. Golden MD, page 22 </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="7" rotate="0">
<textbox bbox="101.710,454.742,636.442,486.782" id="0" size="32.04">2.  Self-limited or chronic condition <textline bbox="101.710,454.742,636.442,486.782" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">2.  Self-limited or chronic condition </textline>
</textbox>
<textbox bbox="69.264,65.296,675.597,404.631" id="1" size="32.048">This is relevant to treatment duration, the  
evolution of the disease and the  
occurrence of adverse reactions/  
interactions, that may require physician  
monitoring. In the case of orlistat, the  
evolution or co-existence of diabetes,  
hypertension or the need for frequent long- 
term INR monitoring if on warfarin are  
serious problems. <textline bbox="69.264,372.567,658.857,404.631" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">This is relevant to treatment duration, the  </textline>
<textline bbox="70.224,334.142,530.254,366.182" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">evolution of the disease and the  </textline>
<textline bbox="70.224,295.742,542.686,327.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">occurrence of adverse reactions/  </textline>
<textline bbox="70.224,257.337,633.396,289.401" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">interactions, that may require physician  </textline>
<textline bbox="70.224,218.922,602.985,250.962" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">monitoring. In the case of orlistat, the  </textline>
<textline bbox="70.224,180.522,606.767,212.562" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">evolution or co-existence of diabetes,  </textline>
<textline bbox="70.224,142.117,675.597,174.181" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">hypertension or the need for frequent long- </textline>
<textline bbox="70.224,103.692,611.796,135.732" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">term INR monitoring if on warfarin are  </textline>
<textline bbox="70.224,65.296,322.507,97.336" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">serious problems. </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="8" rotate="0">
<textbox bbox="136.990,450.182,582.827,482.222" id="0" size="32.04">Findings from Actual Use Study <textline bbox="136.990,450.182,582.827,482.222" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">Findings from Actual Use Study </textline>
</textbox>
<textbox bbox="66.504,307.878,667.924,426.588" id="1" size="27.966">465 of 681 (68%) of eligible subjects had one or  
more labeled exclusions including 24.4% with  
hypertension, 6.8% taking diabetes medication  
and 2.1% taking warfarin <textline bbox="66.504,398.628,667.924,426.588" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">465 of 681 (68%) of eligible subjects had one or  </textline>
<textline bbox="70.224,368.383,642.105,396.367" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">more labeled exclusions including 24.4% with  </textline>
<textline bbox="70.224,338.118,657.440,366.078" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">hypertension, 6.8% taking diabetes medication  </textline>
<textline bbox="70.224,307.878,378.539,335.838" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">and 2.1% taking warfarin </textline>
</textbox>
<textbox bbox="66.504,136.493,666.890,261.898" id="2" size="27.966">Of 247 subjects with conditional labeled 
exclusions, only 32% correctly chose not to use  
or said they would consult a health professional  
first <textline bbox="66.504,233.938,558.628,261.898" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">Of 247 subjects with conditional labeled </textline>
<textline bbox="66.504,196.978,662.835,224.938" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">exclusions, only 32% correctly chose not to use  </textline>
<textline bbox="70.224,166.738,666.890,194.698" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">or said they would consult a health professional  </textline>
<textline bbox="70.224,136.493,115.362,164.477" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">first </textline>
</textbox>
<textbox bbox="74.184,62.552,645.938,90.512" id="3" size="27.96">Correct multivitamin use never exceeded 54% <textline bbox="74.184,62.552,645.938,90.512" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">Correct multivitamin use never exceeded 54% </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="9" rotate="0">
<textbox bbox="63.432,454.742,656.556,486.782" id="0" size="32.04">3.  Benefit / risk ratio and its evaluation <textline bbox="63.432,454.742,656.556,486.782" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">3.  Benefit / risk ratio and its evaluation </textline>
</textbox>
<textbox bbox="66.024,68.072,660.711,405.247" id="1" size="27.964800000000004">This is related to # 1 and #2 because the  
difficulty of continued evaluation of benefit and  
risk by the patient--arguably without any input 
from the physician--can significantly alter this  
ratio and hamper the ability to keep it favorable  
for the patient. A risk that might be tolerable  
under a physician&#8217;s supervision may not be so  
with OTC. The time-related increase in weight  
also alters the benefit / risk ratio, decreasing  
benefit while continuing risks. <textline bbox="66.024,377.263,580.174,405.247" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">This is related to # 1 and #2 because the  </textline>
<textline bbox="70.224,343.638,652.267,371.598" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">difficulty of continued evaluation of benefit and  </textline>
<textline bbox="70.224,310.038,634.843,337.998" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">risk by the patient--arguably without any input </textline>
<textline bbox="74.184,269.718,640.516,297.678" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">from the physician--can significantly alter this  </textline>
<textline bbox="70.224,236.098,660.711,264.058" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">ratio and hamper the ability to keep it favorable  </textline>
<textline bbox="70.224,202.498,616.758,230.458" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">for the patient. A risk that might be tolerable  </textline>
<textline bbox="70.224,168.898,650.869,196.858" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">under a physician&#8217;s supervision may not be so  </textline>
<textline bbox="70.224,135.293,646.632,163.277" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">with OTC. The time-related increase in weight  </textline>
<textline bbox="70.224,101.668,626.153,129.628" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">also alters the benefit / risk ratio, decreasing  </textline>
<textline bbox="70.224,68.072,434.850,96.032" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">benefit while continuing risks. </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="10" rotate="0">
<figure bbox="0.000,0.000,738.000,527.160" height="527" name="Image39" src="Image39.764x546.bmp" width="738">
</figure>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="11" rotate="0">
<textbox bbox="54.912,435.542,677.161,505.982" id="0" size="32.04">4. Adverse drug reactions or interactions 
and the ease of detecting them <textline bbox="54.912,473.942,677.161,505.982" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">4. Adverse drug reactions or interactions </textline>
<textline bbox="131.710,435.542,600.327,467.582" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">and the ease of detecting them </textline>
</textbox>
<textbox bbox="54.000,38.792,650.857,369.198" id="1" size="27.964800000000004">There may be adverse reactions or interactions  
that may not be fully known to the patient or  
physician. This presents  even more  cause for  
concern than the already-troublesome situation  
involving prescription-only drugs. The common  
gastrointestinal adverse reactions and,  
especially the problems in those using warfarin  
or cyclosporine exemplify this as does the  
documented inhibition of fat soluble vitamin  
absorption. <textline bbox="54.000,341.238,648.541,369.198" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">There may be adverse reactions or interactions  </textline>
<textline bbox="58.200,307.638,608.816,335.598" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">that may not be fully known to the patient or  </textline>
<textline bbox="58.200,274.038,645.779,301.998" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">physician. This presents  even more  cause for  </textline>
<textline bbox="58.200,240.433,650.857,268.417" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">concern than the already-troublesome situation  </textline>
<textline bbox="58.200,206.818,645.295,234.778" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">involving prescription-only drugs. The common  </textline>
<textline bbox="58.200,173.218,546.745,201.178" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">gastrointestinal adverse reactions and,  </textline>
<textline bbox="58.200,139.613,648.131,167.597" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">especially the problems in those using warfarin  </textline>
<textline bbox="58.200,105.988,585.526,133.948" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">or cyclosporine exemplify this as does the  </textline>
<textline bbox="58.200,72.392,602.889,100.352" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">documented inhibition of fat soluble vitamin  </textline>
<textline bbox="58.200,38.792,197.049,66.752" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">absorption. </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="12" rotate="0">
<textbox bbox="52.632,432.542,676.227,510.782" id="0" size="32.04">Orlistat, decreased vitamin K absorption  
and warfarin <textline bbox="52.632,478.742,676.227,510.782" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">Orlistat, decreased vitamin K absorption  </textline>
<textline bbox="264.940,432.542,455.226,464.582" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">and warfarin </textline>
</textbox>
<textbox bbox="34.200,41.192,699.538,405.247" id="1" size="27.966545454545454">A few other OTC drugs have warnings about  
concomitant warfarin use. But this problem is  
compounded with orlistat because the drug also  
decreases the absorption of fat-soluble Vitamin K,  
whose &#8221;deficiency&#8221;, induced by warfarin  is the  
mechanism by which warfarin inhibits blood clotting.  
GSK cites a study in that finds no clinically significant  
decrease in blood Vitamin K levels in orlistat users,  
but the study actually finds a statistically significant  
decrease as it did with all other fat soluble vitamins  
that were measured.* <textline bbox="36.600,377.263,595.944,405.247" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">A few other OTC drugs have warnings about  </textline>
<textline bbox="34.200,343.638,599.551,371.598" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">concomitant warfarin use. But this problem is  </textline>
<textline bbox="34.200,310.038,635.703,337.998" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">compounded with orlistat because the drug also  </textline>
<textline bbox="34.200,276.438,660.283,304.398" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">decreases the absorption of fat-soluble Vitamin K,  </textline>
<textline bbox="34.200,242.833,615.260,270.817" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">whose &#8221;deficiency&#8221;, induced by warfarin  is the  </textline>
<textline bbox="34.200,209.218,685.388,237.178" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">mechanism by which warfarin inhibits blood clotting.  </textline>
<textline bbox="34.200,175.618,699.538,203.578" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">GSK cites a study in that finds no clinically significant  </textline>
<textline bbox="34.200,142.013,674.347,169.997" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">decrease in blood Vitamin K levels in orlistat users,  </textline>
<textline bbox="34.200,108.388,670.821,136.348" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">but the study actually finds a statistically significant  </textline>
<textline bbox="34.200,74.792,673.301,102.752" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">decrease as it did with all other fat soluble vitamins  </textline>
<textline bbox="34.200,41.192,300.435,69.152" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">that were measured.* </textline>
</textbox>
<textbox bbox="7.200,1.523,339.381,21.587" id="2" size="18.0">* Diabetes Care. 2004 Mar;27(3):856  <textline bbox="7.200,1.523,339.381,21.587">* Diabetes Care. 2004 Mar;27(3):856  <text bbox="7.200,1.956,14.202,19.956" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="18.000">*</text>
<text bbox="14.160,1.956,19.164,19.956" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="18.000"> </text>
<text bbox="19.200,1.523,33.686,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">D</text>
<text bbox="33.686,1.523,38.140,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">i</text>
<text bbox="38.140,1.523,49.296,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">a</text>
<text bbox="49.296,1.523,60.452,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">b</text>
<text bbox="60.452,1.523,71.607,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">e</text>
<text bbox="71.607,1.523,77.185,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">t</text>
<text bbox="77.185,1.523,88.341,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">e</text>
<text bbox="88.341,1.523,98.373,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">s</text>
<text bbox="98.373,1.523,103.950,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064"> </text>
<text bbox="103.690,1.523,118.176,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">C</text>
<text bbox="118.176,1.523,129.331,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">a</text>
<text bbox="129.331,1.523,136.013,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">r</text>
<text bbox="136.073,1.523,147.228,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">e</text>
<text bbox="147.228,1.523,152.806,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">.</text>
<text bbox="152.806,1.523,158.384,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064"> </text>
<text bbox="158.023,1.523,169.178,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">2</text>
<text bbox="169.178,1.523,180.334,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">0</text>
<text bbox="180.334,1.523,191.490,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">0</text>
<text bbox="191.490,1.523,202.645,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">4</text>
<text bbox="202.645,1.523,208.223,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064"> </text>
<text bbox="208.062,1.523,224.776,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">M</text>
<text bbox="224.776,1.523,235.931,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">a</text>
<text bbox="235.931,1.523,242.613,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">r</text>
<text bbox="242.613,1.523,248.190,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">;</text>
<text bbox="248.190,1.523,259.346,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">2</text>
<text bbox="259.346,1.523,270.502,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">7</text>
<text bbox="270.502,1.523,277.183,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">(</text>
<text bbox="277.183,1.523,288.338,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">3</text>
<text bbox="288.338,1.523,295.020,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">)</text>
<text bbox="294.940,1.523,300.517,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">:</text>
<text bbox="300.517,1.523,311.673,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">8</text>
<text bbox="311.492,1.523,322.648,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">5</text>
<text bbox="322.648,1.523,333.804,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">6</text>
<text bbox="333.804,1.523,339.381,21.587" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064"> </text>
</textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="13" rotate="0">
<textbox bbox="33.840,61.592,719.472,508.412" id="0" size="28.220999999999997">5. Long-term data from prescription use 
Problems that have arisen and been documented  
during use in prescription form are likely, if not  certain,  
to be more common and/or more serious in the OTC  
version. There are 39 cases of increased INR  
(abnormal blood thinning) in orlistat users, include 29  
taking warfarin, one with Vitamin K deficiency not  
using warfarin, one death, 10 hospitalizations, four  
with life-threatening reactions and reports by the FDA  
of several patients with bleeding episodes.* More of  
these would inevitably occur with OTC use as  
evidenced by the fact that 50% of 14 warfarin users  
chose to use OTC orlistat and might not have told their  
physician and thereby get weekly INR monitoring  
when first using orlistat, as recommended by  
MacWalters, et al.** <textline bbox="42.960,476.372,648.501,508.412" colourspace="DeviceGray" font="Arial-BoldMT" ncolour="1" size="32.040">5. Long-term data from prescription use </textline>
<textline bbox="33.840,437.988,653.909,465.948" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">Problems that have arisen and been documented  </textline>
<textline bbox="34.200,411.108,719.108,439.068" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">during use in prescription form are likely, if not  certain,  </textline>
<textline bbox="34.200,384.223,691.544,412.207" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">to be more common and/or more serious in the OTC  </textline>
<textline bbox="34.200,357.343,605.465,385.327" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">version. There are 39 cases of increased INR  </textline>
<textline bbox="34.200,330.438,699.620,358.398" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">(abnormal blood thinning) in orlistat users, include 29  </textline>
<textline bbox="34.200,303.558,650.438,331.518" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">taking warfarin, one with Vitamin K deficiency not  </textline>
<textline bbox="34.200,276.678,666.711,304.638" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">using warfarin, one death, 10 hospitalizations, four  </textline>
<textline bbox="34.200,249.793,702.421,277.777" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">with life-threatening reactions and reports by the FDA  </textline>
<textline bbox="34.200,222.898,682.229,250.858" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">of several patients with bleeding episodes.* More of  </textline>
<textline bbox="34.200,196.018,607.352,223.978" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">these would inevitably occur with OTC use as  </textline>
<textline bbox="34.200,169.138,678.986,197.098" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">evidenced by the fact that 50% of 14 warfarin users  </textline>
<textline bbox="34.200,142.253,719.472,170.237" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.984">chose to use OTC orlistat and might not have told their  </textline>
<textline bbox="34.200,115.348,649.320,143.308" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">physician and thereby get weekly INR monitoring  </textline>
<textline bbox="34.200,88.472,596.476,116.432" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">when first using orlistat, as recommended by  </textline>
<textline bbox="34.200,61.592,278.990,89.552" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="27.960">MacWalters, et al.** </textline>
</textbox>
<textbox bbox="7.200,3.899,696.327,52.696" id="1" size="20.052">* FDA AERS files 
**Ann Pharmacother. 2003 Apr;37(4):510-2.  Orlistat enhances warfarin effect. <textline bbox="7.200,32.656,159.524,52.696" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.040">* FDA AERS files </textline>
<textline bbox="7.200,3.899,696.327,23.963" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">**Ann Pharmacother. 2003 Apr;37(4):510-2.  Orlistat enhances warfarin effect. </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="14" rotate="0">
<textbox bbox="261.820,452.350,458.056,488.350" id="0" size="36.0">Conclusions <textline bbox="261.820,452.350,458.056,488.350" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="36.000">Conclusions </textline>
</textbox>
<textbox bbox="7.200,83.296,707.392,422.612" id="1" size="32.04533333333333">1. For the reasons discussed, the switch of  
orlistat to OTC status would be a serious,  
dangerous mistake in light of its marginal  
benefits, frequent co-existence of other  
diseases, common, bothersome G-I adverse  
reactions, significant inhibition of absorption of  
fat soluble vitamins, and problematic use in the  
millions of people* using warfarin or, less  
commonly, cyclosporine. <textline bbox="7.200,390.572,622.107,422.612" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">1. For the reasons discussed, the switch of  </textline>
<textline bbox="34.200,352.142,627.517,384.182" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">orlistat to OTC status would be a serious,  </textline>
<textline bbox="34.200,313.742,622.102,345.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">dangerous mistake in light of its marginal  </textline>
<textline bbox="34.200,275.342,595.484,307.382" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">benefits, frequent co-existence of other  </textline>
<textline bbox="34.200,236.937,672.052,269.001" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">diseases, common, bothersome G-I adverse  </textline>
<textline bbox="34.200,198.522,696.723,230.562" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">reactions, significant inhibition of absorption of  </textline>
<textline bbox="34.200,160.122,707.392,192.162" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">fat soluble vitamins, and problematic use in the  </textline>
<textline bbox="34.200,121.717,620.362,153.781" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">millions of people* using warfarin or, less  </textline>
<textline bbox="34.200,83.296,382.090,115.336" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">commonly, cyclosporine. </textline>
</textbox>
<textbox bbox="7.200,2.651,313.537,46.696" id="2" size="20.052">*23 million prescriptions filled for  
warfarin in 2004: Drug Topics Data <textline bbox="7.200,26.656,299.584,46.696" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.040">*23 million prescriptions filled for  </textline>
<textline bbox="7.200,2.651,313.537,22.715" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="20.064">warfarin in 2004: Drug Topics Data </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="15" rotate="0">
<textbox bbox="265.900,452.350,454.036,488.350" id="0" size="36.0">(Continued) <textline bbox="265.900,452.350,454.036,488.350" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="36.000">(Continued) </textline>
</textbox>
<textbox bbox="60.984,103.692,682.705,404.631" id="1" size="32.049">2.  Physicians are increasingly rejecting the  
prescribing of orlistat (decrease from 2.6  
million US prescriptions in f.y. 2000 to 1.0  
million in f.y. 2004). It is clearly in GSK&#8217;s  
(and partner Roche&#8217;s) interest to seek  
OTC approval. Your committees need to  
reject this desperate attempt to revive this  
barely effective drug by an OTC switch.  <textline bbox="60.984,372.567,682.705,404.631" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">2.  Physicians are increasingly rejecting the  </textline>
<textline bbox="70.224,334.142,650.853,366.182" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">prescribing of orlistat (decrease from 2.6  </textline>
<textline bbox="70.224,295.742,664.630,327.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">million US prescriptions in f.y. 2000 to 1.0  </textline>
<textline bbox="70.224,257.337,644.715,289.401" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">million in f.y. 2004). It is clearly in GSK&#8217;s  </textline>
<textline bbox="70.224,218.922,613.142,250.962" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">(and partner Roche&#8217;s) interest to seek  </textline>
<textline bbox="70.224,180.522,647.489,212.562" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">OTC approval. Your committees need to  </textline>
<textline bbox="70.224,142.117,670.526,174.181" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">reject this desperate attempt to revive this  </textline>
<textline bbox="70.224,103.692,636.339,135.732" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">barely effective drug by an OTC switch.  </textline>
</textbox>
</page>
<page bbox="0.000,0.000,720.000,540.000" id="16" rotate="0">
<textbox bbox="255.700,450.078,464.451,490.038" id="0" size="39.96">(Continued) <textline bbox="255.700,450.078,464.451,490.038" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="39.960">(Continued) </textline>
</textbox>
<textbox bbox="43.200,103.692,716.101,404.631" id="1" size="32.049">3.&#8220;though a statistically significant weight loss  
for orlistat 60 mg compared to placebo is  
seen, there is no evidence presented that a  
modest, transient weight loss due to orlistat  
will afford any long-term clinical benefit either  
through a change in behaviour or a reduced  
risk of serious clinical diseases manifest by  
being overweight.&#8221; <textline bbox="43.200,372.567,695.157,404.631" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">3.&#8220;though a statistically significant weight loss  </textline>
<textline bbox="70.224,334.142,656.268,366.182" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">for orlistat 60 mg compared to placebo is  </textline>
<textline bbox="70.224,295.742,691.768,327.782" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">seen, there is no evidence presented that a  </textline>
<textline bbox="70.224,257.337,691.945,289.401" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">modest, transient weight loss due to orlistat  </textline>
<textline bbox="70.224,218.922,716.101,250.962" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">will afford any long-term clinical benefit either  </textline>
<textline bbox="70.224,180.522,698.913,212.562" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">through a change in behaviour or a reduced  </textline>
<textline bbox="70.224,142.117,688.546,174.181" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.064">risk of serious clinical diseases manifest by  </textline>
<textline bbox="70.224,103.692,331.542,135.732" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="32.040">being overweight.&#8221; </textline>
</textbox>
<textbox bbox="7.200,17.004,232.092,35.004" id="2" size="18.0">FDA Statistical Review, p 22 <textline bbox="7.200,17.004,232.092,35.004" colourspace="DeviceGray" font="ArialMT" ncolour="1" size="18.000">FDA Statistical Review, p 22 </textline>
</textbox>
</page>
</pages>